To explore the role of the DCLK1 kinase domain in CRC aggressiveness, we performed a series of in vitro experiments using DCLK1-IN-1 20, a recently discovered selective DCLK1 inhibitor that selectively generates a considerable conformational shift in the ATP binding site inside the kinase domain without interfering with the DCX domain 21. The gene discussed is DCX; the disease is colorectal carcinoma.